Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide - Novo Nordisk

Drug Profile

Liraglutide - Novo Nordisk

Alternative Names: LATIN T1D; Liraglutide; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 21 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk; University of Pennsylvania
  • Developer Cedars-Sinai Medical Center; Hvidovre Hospital; Novo Nordisk
  • Class Antihyperglycaemics; Antiparkinsonians; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease; Smoking withdrawal
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 21 Dec 2018 Phase-II clinical trials in Smoking withdrawal in USA (Injection) (NCT03712098)
  • 22 Oct 2018 The US FDA approves updated label with cardiovascular safety data at lower dose for liraglutide (Saxenda®)
  • 01 Oct 2018 Updated efficacy and adverse events data from the phase III LEADER trial in Type-2 diabetes mellitus presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top